

Douwe Postmus

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6921357/publications.pdf>

Version: 2024-02-01

66
papers

2,102
citations

201674

27
h-index

243625

44
g-index

67
all docs

67
docs citations

67
times ranked

3396
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term outcomes of atrioventricular septal defect and single ventricle: A multicenter study. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 163, 1166-1175.	0.8	7
2	Parenteral Prostanoids in Pediatric Pulmonary Arterial Hypertension: Start Early, Dose High, Combine. <i>Annals of the American Thoracic Society</i> , 2022, 19, 227-237.	3.2	16
3	Determinants of quality of life in acute heart failure patients with and without comorbidities: a prospective, observational study. <i>European Journal of Cardiovascular Nursing</i> , 2022, 21, 205-212.	0.9	10
4	A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. <i>Kidney International</i> , 2022, 101, 174-184.	5.2	53
5	Prediction of Poor Outcome for Cutaneous Squamous Cell Carcinoma of the Head and Neck Comparing Classification Systems: A Competing Risk Analysis. <i>Journal of Investigative Dermatology</i> , 2022, 142, 2532-2534.e4.	0.7	2
6	Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease. <i>Circulation</i> , 2021, 143, 438-448.	1.6	85
7	Using joint modelling to assess the association between a time-varying biomarker and a survival outcome: an illustrative example in respiratory medicine. <i>European Respiratory Journal</i> , 2021, 57, 2003206.	6.7	6
8	A heart failure phenotype stratified model for predicting 1-year mortality in patients admitted with acute heart failure: results from an individual participant data meta-analysis of four prospective European cohorts. <i>BMC Medicine</i> , 2021, 19, 21.	5.5	5
9	Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 807-820.	4.1	49
10	Association of Early Blood Pressure Decrease and Renal Function With Prognosis in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 890-903.	4.1	7
11	Derivation and validation of a prognostic model for predicting in-hospital mortality in patients admitted with COVID-19 in Wuhan, China: the PLANS (platelet lymphocyte age neutrophil sex) model. <i>BMC Infectious Diseases</i> , 2020, 20, 959.	2.9	11
12	Urinary sulfate excretion and risk of late graft failure in renal transplant recipients – a prospective cohort study. <i>Transplant International</i> , 2020, 33, 752-761.	1.6	6
13	Differences in Importance Attached to Drug Effects Between Patients With Type 2 Diabetes From the Netherlands and Turkey: A Preference Study. <i>Frontiers in Pharmacology</i> , 2020, 11, 617409.	3.5	1
14	Hepatorenal dysfunction identifies high-risk patients with acute heart failure: insights from the RELAX-AHF trial. <i>ESC Heart Failure</i> , 2019, 6, 1188-1198.	3.1	22
15	From Individual to Population Preferences: Comparison of Discrete Choice and Dirichlet Models for Treatment Benefit-Risk Tradeoffs. <i>Medical Decision Making</i> , 2019, 39, 879-885.	2.4	7
16	Understanding Patients' Preferences: A Systematic Review of Psychological Instruments Used in Patients' Preference and Decision Studies. <i>Value in Health</i> , 2019, 22, 491-501.	0.3	51
17	Stratified treatment recommendation or one-size-fits-all? A health economic insight based on graphical exploration. <i>European Journal of Health Economics</i> , 2019, 20, 475-482.	2.8	1
18	Individual Trade-Offs Between Possible Benefits and Risks of Cancer Treatments: Results from a Stated Preference Study with Patients with Multiple Myeloma. <i>Oncologist</i> , 2018, 23, 44-51.	3.7	53

#	ARTICLE	IF	CITATIONS
19	Serially measured circulating microRNAs and adverse clinical outcomes in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 89-96.	7.1	48
20	Diagnostic reliability of low dose multidetector CT and cone beam CT in maxillofacial trauma—an experimental blinded and randomized study. <i>Dentomaxillofacial Radiology</i> , 2018, 47, 20170423.	2.7	14
21	The early economic evaluation of novel biomarkers to accelerate their translation into clinical applications. <i>Cost Effectiveness and Resource Allocation</i> , 2018, 16, 23.	1.5	9
22	Mediterranean style diet is associated with low risk of new-onset diabetes after renal transplantation. <i>BMJ Open Diabetes Research and Care</i> , 2017, 5, e000283.	2.8	43
23	Plasma biomarkers to predict or rule out early post-discharge events after hospitalization for acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 728-738.	7.1	34
24	Prognostic Value of Serial ST2 Measurements in Patients With Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2378-2388.	2.8	108
25	Prognostic Value of Serial Galectin-3 Measurements in Patients With Acute Heart Failure. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	24
26	Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 281-293.	2.6	8
27	Incorporating patient preferences into drug development and regulatory decision making: Results from a quantitative pilot study with cancer patients, carers, and regulators. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 99, 548-554.	4.7	70
28	Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the PROTECT study. <i>European Journal of Heart Failure</i> , 2016, 18, 830-839.	7.1	70
29	THE EARLY BIRD CATCHES THE WORM: EARLY COST-EFFECTIVENESS ANALYSIS OF NEW MEDICAL TESTS. <i>International Journal of Technology Assessment in Health Care</i> , 2016, 32, 46-53.	0.5	32
30	Risk-based evaluation of efficacy of rolofylline in patients hospitalized with acute heart failure—a Post-hoc analysis of the PROTECT trial. <i>International Journal of Cardiology</i> , 2016, 223, 967-975.	1.7	6
31	Continuous-Time Semi-Markov Models in Health Economic Decision Making. <i>Medical Decision Making</i> , 2016, 36, 59-71.	2.4	15
32	Tools and Techniques—Statistical. Estimating cumulative incidences in the presence of right-censoring and competing risks: an introduction with illustrations from the COACH study. <i>EuroIntervention</i> , 2016, 11, e1322-e1324.	3.2	0
33	Assessment of Cotinine Reveals a Dose-Dependent Effect of Smoking Exposure on Long-term Outcomes After Renal Transplantation. <i>Transplantation</i> , 2015, 99, 1926-1932.	1.0	11
34	Graphical assessment of incremental value of novel markers in prediction models: From statistical to decision analytical perspectives. <i>Biometrical Journal</i> , 2015, 57, 556-570.	1.0	21
35	Using Multicriteria Decision Analysis to Support Research Priority Setting in Biomedical Translational Research Projects. <i>BioMed Research International</i> , 2015, 2015, 1-9.	1.9	7
36	Applying Multiple Criteria Decision Analysis to Comparative Benefit-Risk Assessment. <i>Medical Decision Making</i> , 2015, 35, 859-871.	2.4	44

#	ARTICLE	IF	CITATIONS
37	Should non-cardiovascular mortality be considered in the SCORE model? Findings from the Prevention of Renal and Vascular End-stage Disease (PREVEND) cohort. <i>European Journal of Epidemiology</i> , 2015, 30, 47-56.	5.7	3
38	Design of stepwise screening for prediabetes and type 2 diabetes based on costs and cases detected. <i>Journal of Clinical Epidemiology</i> , 2015, 68, 1010-1018.	5.0	5
39	Hemoglobin levels and new-onset heart failure in the community. <i>American Heart Journal</i> , 2015, 169, 94-101.e2.	2.7	18
40	A multi-criteria decision analysis perspective on the health economic evaluation of medical interventions. <i>European Journal of Health Economics</i> , 2014, 15, 709-716.	2.8	18
41	Renal Function Trajectories and Clinical Outcomes in Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 59-67.	3.9	60
42	Notes on "Hit-And-Run enables efficient weight generation for simulation-based multiple criteria decision analysis"™. <i>European Journal of Operational Research</i> , 2014, 239, 865-867.	5.7	31
43	Probability Elicitation to Inform Early Health Economic Evaluations of New Medical Technologies: A Case Study in Heart Failure Disease Management. <i>Value in Health</i> , 2013, 16, 529-535.	0.3	24
44	The WAP Four-Disulfide Core Domain Protein HE4: A Novel Biomarker for Heart Failure. <i>JACC: Heart Failure</i> , 2013, 1, 164-169.	4.1	40
45	The Predictive Value of Short-Term Changes in Hemoglobin Concentration in Patients Presenting With Acute Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1973-1981.	2.8	159
46	Hit-And-Run enables efficient weight generation for simulation-based multiple criteria decision analysis. <i>European Journal of Operational Research</i> , 2013, 224, 552-559.	5.7	122
47	Microsimulation for Clinical Decision-Making in Individual Patients With Established Coronary Artery Disease. <i>Circulation Journal</i> , 2013, 77, 717-724.	1.6	5
48	Peroxiredoxin 4, A Novel Circulating Biomarker for Oxidative Stress and the Risk of Incident Cardiovascular Disease and All-Cause Mortality. <i>Journal of the American Heart Association</i> , 2012, 1, e002956.	3.7	42
49	The COACH risk engine: a multistate model for predicting survival and hospitalization in patients with heart failure. <i>European Journal of Heart Failure</i> , 2012, 14, 168-175.	7.1	42
50	Long-Term Compliance With Nonpharmacologic Treatment of Patients With Heart Failure. <i>American Journal of Cardiology</i> , 2012, 110, 392-397.	1.6	48
51	Incidence of impaired renal function after lung transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, 238-243.	0.6	17
52	Multicriteria benefit-risk assessment using network meta-analysis. <i>Journal of Clinical Epidemiology</i> , 2012, 65, 394-403.	5.0	63
53	A method for the early health technology assessment of novel biomarker measurement in primary prevention programs. <i>Statistics in Medicine</i> , 2012, 31, 2733-2744.	1.6	18
54	Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study. <i>Diabetologia</i> , 2012, 55, 1963-1970.	6.3	66

#	ARTICLE	IF	CITATIONS
55	A trial-based economic evaluation of 2 nurse-led disease management programs in heart failure. American Heart Journal, 2011, 162, 1096-1104.	2.7	33
56	Survival and Quality of Life After Stereotactic or 3D-Conformal Radiotherapy for Inoperable Early-Stage Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 81, e291-e297.	0.8	76
57	Former Smoking Is a Risk Factor for Chronic Kidney Disease After Lung Transplantation. American Journal of Transplantation, 2011, 11, 2490-2498.	4.7	23
58	Quantitative release planning in extreme programming. Information and Software Technology, 2011, 53, 1227-1235.	4.4	24
59	Plasma procalcitonin and risk of type 2 diabetes in the general population. Diabetologia, 2011, 54, 2463-2465.	6.3	25
60	A stochastic multicriteria model for evidence-based decision making in drug benefit-risk analysis. Statistics in Medicine, 2011, 30, 1419-1428.	1.6	88
61	A polymorphism in the gene encoding carnosinase (CNDP1) as a predictor of mortality and progression from nephropathy to end-stage renal disease in type 1 diabetes mellitus. Diabetologia, 2010, 53, 2562-2568.	6.3	19
62	Plasma Procalcitonin Is Associated with Obesity, Insulin Resistance, and the Metabolic Syndrome. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E26-E31.	3.6	49
63	Product and Release Planning Practices for Extreme Programming. Lecture Notes in Business Information Processing, 2010, , 238-243.	1.0	3
64	An economic model to compare the profitability of pay-per-use and fixed-fee licensing. Information and Software Technology, 2009, 51, 581-588.	4.4	17
65	Aligning the economic modeling of software reuse with reuse practices. Information and Software Technology, 2008, 50, 753-762.	4.4	8
66	Towards Model-driven Evolvability of Enterprise Information Systems. , 2006, , .		0